These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 35884392)

  • 1. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
    Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
    Ouyang T; Kan X; Zheng C
    Front Oncol; 2022; 12():898964. PubMed ID: 35785169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy for hepatocellular carcinoma.
    Rimassa L; Finn RS; Sangro B
    J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
    Lee MMP; Chan LL; Chan SL
    J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
    Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
    Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
    Pinto E; Meneghel P; Farinati F; Russo FP; Pelizzaro F; Gambato M
    Dig Liver Dis; 2024 Apr; 56(4):579-588. PubMed ID: 37758610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting.
    Plaz Torres MC; Lai Q; Piscaglia F; Caturelli E; Cabibbo G; Biasini E; Pelizzaro F; Marra F; Trevisani F; Giannini EG
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
    Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
    Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in the Treatment of HCC.
    Donisi C; Puzzoni M; Ziranu P; Lai E; Mariani S; Saba G; Impera V; Dubois M; Persano M; Migliari M; Pretta A; Liscia N; Astara G; Scartozzi M
    Front Oncol; 2020; 10():601240. PubMed ID: 33585218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapies for advanced hepatocellular carcinoma.
    Sun LY; Zhang KJ; Xie YM; Liu JW; Xiao ZQ
    Front Pharmacol; 2023; 14():1138493. PubMed ID: 37025485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
    Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
    Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
    Federico P; Petrillo A; Giordano P; Bosso D; Fabbrocini A; Ottaviano M; Rosanova M; Silvestri A; Tufo A; Cozzolino A; Daniele B
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
    Tovoli F; De Lorenzo S; Trevisani F
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33023131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.
    Liu ZL; Liu JH; Staiculescu D; Chen J
    Ther Adv Med Oncol; 2021; 13():17588359211018026. PubMed ID: 34104226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.